Search

Your search keyword '"Thomas Erker"' showing total 186 results

Search Constraints

Start Over You searched for: Author "Thomas Erker" Remove constraint Author: "Thomas Erker"
186 results on '"Thomas Erker"'

Search Results

1. Role of NKCC1 Activity in Glioma K+ Homeostasis and Cell Growth: New Insights With the Bumetanide-Derivative STS66

2. Novel Promising Estrogenic Receptor Modulators: Cytotoxic and Estrogenic Activity of Benzanilides and Dithiobenzanilides.

Catalog

Books, media, physical & digital resources

3. Foam cell specific LXRα ligand.

4. A Novel Na + -K + -Cl − Cotransporter 1 Inhibitor STS66* Reduces Brain Damage in Mice After Ischemic Stroke

6. Role of NKCC1 Activity in Glioma K+ Homeostasis and Cell Growth: New Insights With the Bumetanide-Derivative STS66

7. Impaired chloride homeostasis in epilepsy: Molecular basis, impact on treatment, and current treatment approaches

8. Functional characterization of novel bumetanide derivatives for epilepsy treatment

9. A Novel Na

10. The search for NKCC1-selective drugs for the treatment of epilepsy: Structure–function relationship of bumetanide and various bumetanide derivatives in inhibiting the human cation-chloride cotransporter NKCC1A

11. The bumetanide prodrug BUM5, but not bumetanide, potentiates the antiseizure effect of phenobarbital in adult epileptic mice

14. The role of oxidative stress in 63 T-induced cytotoxicity against human lung cancer and normal lung fibroblast cell lines

15. Effects of novel NKCC1 inhibitors on reducing brain damage and neurological deficits after ischemic stroke in mice

16. Hydrogen sulphide induces HIF-1α and Nrf2 in THP-1 macrophages

17. Bumetanide is not capable of terminating status epilepticus but enhances phenobarbital efficacy in different rat models

18. Resveratrol post-transcriptionally regulates pro-inflammatory gene expression via regulation of KSRP RNA binding activity

19. A novel prodrug-based strategy to increase effects of bumetanide in epilepsy

20. Synthesis, biological evaluation and 3D-QSAR studies of new chalcone derivatives as inhibitors of human P-glycoprotein

21. GABAA receptor modulation by piperine and a non-TRPV1 activating derivative

22. Tariquidar and Elacridar Are Dose-Dependently Transported by P-Glycoprotein and Bcrp at the Blood-Brain Barrier: A Small-Animal Positron Emission Tomography and In Vitro Study

23. Multiple blood-brain barrier transport mechanisms limit bumetanide accumulation, and therapeutic potential, in the mammalian brain

24. Selective anticancer activity of the novel thiobenzanilide 63T against human lung adenocarcinoma cells

25. The exploration of thienothiazines as selective butyrylcholinesterase inhibitors

26. The antiepileptic drug mephobarbital is not transported by P-glycoprotein or multidrug resistance protein 1 at the blood–brain barrier: A positron emission tomography study

27. A comparative small-animal PET evaluation of [C-11]tariquidar, [C-11]elacridar and (R)-[C-11]verapamil for detection of P-glycoprotein-expressing murine breast cancer

29. Synthesis and Biological Activity of Thienodiltiazem in Isolated Heart Muscle Preparations of Guinea Pigs

30. PET and SPECT Radiotracers to Assess Function and Expression of ABC Transporters In Vivo

31. Radiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein

32. Interaction of diltiazem with an intracellularly accessible binding site on CaV1.2

33. Synthesis, spasmolytic activity and structure–activity relationship study of a series of polypharmacological thiobenzanilides

34. A journey from benzanilides to dithiobenzanilides: Synthesis of selective spasmolytic compounds

35. Resveratrol blocks Akt activation in angiotensin II- or EGF-stimulated vascular smooth muscle cells in a redox-independent manner

36. Valerenic acid derivatives as novel subunit-selective GABAA receptor ligands -in vitro and in vivo characterization

37. Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate

38. Synthesis and Small-Animal Positron Emission Tomography Evaluation of [11C]-Elacridar As a Radiotracer to Assess the Distribution of P-Glycoprotein at the Blood−Brain Barrier

39. Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells

40. Benzanilides with spasmolytic activity: Chemistry, pharmacology, and SAR

41. Synthesis and cytotoxic activity of resveratrol-based compounds

42. ‘Bridged’ stilbene derivatives as selective cyclooxygenase-1 inhibitors

43. Drug trapping in hERG K

44. Enhanced Antiproliferative and Pro-apoptotic Activities of a Novel Curcumin-related Compound in Jurkat Leukemia T-Cells

45. Discovery of small molecules with vasodilating characteristics and adjustable hydrolytic behavior

46. SAR-guided development and characterization of a potent antitumor compound toward B-cell neoplasms with no detectable cytotoxicity toward healthy cells

47. Cytotoxic and biochemical effects of 3,3′,4,4′,5,5′-hexahydroxystilbene, a novel resveratrol analog in HL-60 human promyelocytic leukemia cells

48. Synthesis of fluorine-18-labelled 5- and 6-fluoro-2-pyridinamine

49. Completion of the Spectroscopical Data for the Synthesis of DIMBOA

50. Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure–activity relationship